Edwards Lifesciences Corporation
EW
$83.39
$0.951.15%
NYSE
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -12.64% | -6.93% | -7.16% | -87.44% | 738.33% |
| Total Depreciation and Amortization | 2.89% | 4.10% | -14.08% | 23.48% | -12.88% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -43.16% | 1,029.11% | 108.53% | 97.31% | -36,464.89% |
| Change in Net Operating Assets | 213.15% | -39.48% | 73.63% | -167.74% | 2,834.40% |
| Cash from Operations | 97.69% | 3.50% | 319.92% | -136.24% | -5.30% |
| Capital Expenditure | -16.63% | 11.96% | -12.45% | 4.05% | 39.23% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | 60.95% | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -201.55% | -186.91% | 161.78% | -106.50% | 1,573.26% |
| Cash from Investing | -148.58% | -301.76% | 114.79% | -121.35% | 2,064.82% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -65.88% | 103.81% | 74.48% | -17.10% | -36.46% |
| Repurchase of Common Stock | -- | -- | -308,500.00% | 99.99% | -469.89% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -279.80% | -7,100.00% | 600.00% | 100.09% | -1,630.56% |
| Cash from Financing | -1,504.36% | 120.43% | -1,002.10% | 102.93% | -911.08% |
| Foreign Exchange rate Adjustments | 96.62% | -67.23% | -134.71% | 199.03% | -275.17% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -521.53% | 56.89% | 114.41% | -130.84% | 371.99% |